The new machine features enhancements designed to simplify treatment, increase ease of learning and improve user experience.
NxStage Versi HD with GuideMe software picked up FDA clearance in 2023. Fresenius Medical Care says its system has since picked up significant interest in the U.S. as large, mid-sized and independent dialysis providers continue to adopt the company’s latest home hemodialysis system.
Fresenius Medical Care designed the advanced software to simplify HHD treatment. It aims to improve ease of learning, skill retention and user experience for patients and caregivers.
The machine features pictorial-based guidance designed to meet diverse patient needs throughout the setup, treatment and troubleshooting. It provides graphical walk-through guidance that aims to enhance ease of use and confidence for both patients and nurses. The interface accommodates a range of learning styles and helps improve skill retention from initial training. Meanwhile, static picture instructions allow patients to linger and study any step at their own pace.
In addition to the launch, Fresenius Medical Care said it reached the milestone of more than 14,000 U.S. patients using its NxStage HHD therapy. The milestone comes through patients using both its Fresenius Kidney Care clinics and other providers.
“We are proud to announce these achievements in our Home Therapies division,” said Joseph Turk, EVP and global head of Home Therapies at Fresenius Medical Care. “These accomplishments underscore our relentless commitment to continuous innovations that enable us to improve the lives of patients seeking the safety, convenience, and flexibility of home dialysis.”
